Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

SinocellTech Says Anti-CD20 mAb Shows Non-Inferiority to Genetech’s Rituxan

publication date: Aug 16, 2022

Beijing's SinocellTech reported that its anti-CD20 McAb, ripertamab, proved non-inferiority to Genentech’s rituximab (Rituxan) in a China Phase III trial. The trial enrolled 364 patients with primary diffuse large B-cell lymphoma (DLBCL). The Objective Response Rate was 94% in both cohorts with safety events also very similar. In 2018, SinocellTech out-licensed rights for ripertamab to CSPC Pharma in a deal worth up to $98 million plus sales milestones. SinocellTech’s pipeline consists of 23 products including 21 novel differentiated drugs and two biosimilars. More details....

Stock Symbol: (SHA: 688520)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital